TY  - JOUR
AU  - Widysanto, Allen
AU  - Prasetya, Ignatius Bima
AU  - Meriyanti, Tandry
AU  - Sungono, Veli
AU  - Setiawan, Diane Lukito
AU  - Gunawan, Edy
AU  - Adiputra, Bayu
AU  - Lorens, Jane Olivia
AU  - Santi, Theresia
AU  - Pradhana, Cindy Meidy Leony
AU  - Yusuf, Irawan
AU  - Gunawan, Catherine
PY  - 2022
TI  - The risk factors of SARS-CoV-2 antibody level differences in healthcare workers post vaccination in Siloam hospitals: A nationwide multicenter study
JO  - Infectious Medicine
SN  - 2097-0684
SP  - 229
EP  - 235
VL  - 1
IS  - 4
AB  - BackgroundSeveral vaccines have been approved against COVID-19, and 5 have been used in Indonesia. Due to the decrease in antibody levels 3 to 6 months after the second dose of CoronaVac, healthcare workers received the third booster of mRNA vaccine (mRNA-1273) to increase the antibody level. This study aimed to evaluate the risk factors of anti-S-RBD IgG levels differences in healthcare workers.MethodsThis study is a retrospective cohort study of 576 healthcare workers without previous SARS-CoV-2 infection who received 2 doses of CoronaVac and the third dose of mRNA-1273 6 months after the second dose. Blood samples were obtained 2nd, 6th, 12th, and 24th weeks after the second dose of CoronaVac vaccine administration, with mRNA-1273 booster on week 20. Quantitative measurements of IgG antibodies were performed with Elecsys Anti-SARS-CoV-2 S immunoassay. We identify the baseline factors predicting post-vaccination antibody titers using univariate and multivariate linear regression analysis.ResultsThis study comprised 576 participants aged 32 years old, 72.05% female, and 45.84% from high-risk occupation subgroups. The median antibodies titer level on the 2nd, 6th, 12th, and 24th weeks after the second vaccine dose administration were 40.99 u/mL, 42.01 u/mL, 54.78 u/mL, and 23,225 u/mL. Antibody levels trended highest in female and younger age group (20-29 years old).ConclusionsThe third dose of vaccine increased the quantitative SARS-CoV-2 spike IgG antibody titers and eliminated differences in antibodies titer by gender.
UR  - https://doi.org/10.1016/j.imj.2022.10.001
DO  - 10.1016/j.imj.2022.10.001